Skip to main content

Advertisement

Table 2 Demographic data, smoking, comorbidities and functional, radiological and clinical parameters of the sarcoidosis cohort, divided into steroid-free and treated

From: Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis

 Sarcoidosis steroid-freeSarcoidosis on therapyp-value
370324 
Male (%)160 (43)128 (39.5)0.4012
Age (years)55.6 ± 14.954.2 ± 13.40.5978
Smoking history (pack/year)4.8 ± 105.1 ± 10.40.1849
 • Current (%)18 (4.8)19 (5.8)0.4012
 • Former (%)117 (31.6)79 (24.3)0.4012
 • Never (%)235 (63.5)226 (69.7)0.4012
Biomarkers determination (basal sampling)
 • Chitotriosidase nmol/ml/h180.1 ± 99.2168.2 ± 118.20.3210
 • ACE UI/ml49.3 ± 24.248.5 ± 24.80.5031
 • Lysozyme mg/dl5.8 ± 1.85.4 ± 2.40.8265
Comorbidities228 (61.2%)199 (61.4%)0.7887
 • Arterial Hypertension (%)93 (25.1)67 (20.4)0.1624
 • Diabetes Mellitus (%)21 (5.6)27 (8.3)0.0578
 • Osteopenia/Osteoporosis (%)112 (30.2)110 (33.9)0.1875
 • Thyroid disorder (%)29 (7.8)25 (7.7)0.9410
 • Psychiatric disorder (%)14 (3.7)18 (5.5)0.2178
 • GERD/Hiatal ernia (%)32 (8.6)31 (9.5)0.5264
 • Other (%)29 (7.8)33 (10.1)0.1765
PFTs
 • FVC l (%)3.6 ± 1.1 (105.7 ± 18.2)3.5 ± 1.1 (104.2 ± 18.4)0.2455
 • FEV1 l (%)2.8 ± 0.9 (98.5 ± 19)2.7 ± 1 (95.8 ± 19)0.0945
 • FEV1/FVC76.1 ± 7.875.8 ± 8.70.6210
 • TLC l (%)6.3 ± 1.6 (110.8 ± 18.8)6.1 ± 1.4 (109.1 ± 16.9)0.3401
 • DLCO %83.1 ± 15.677.7 ± 16.90.002
 • KCO %92.7 ± 15.889.6 ± 15.80.0089
Radiological assessment (Scadding)
 • Stage 0 (%)177 (47.8)116 (35)<0.0001
 • Stage 1 (%)45 (12.1)28 (9)<0.0001
 • Stage 2 (%)56 (15.1)67 (21)< 0.0001
 • Stage 3 (%)81 (21.8)83 (24)<0.0001
 • Stage 4 (%)11 (2.9)30 (10)<0.0001
Clinical assessment
 • No symptoms (%)145 (39.1)98 (30.2)0.0123
 • Cough (%)132 (35.6)110 (33.9)0.8812
 • Dyspnea (%)155 (41.8)133 (41)0.8120
 • Asthenia (%)118 (31.8)119 (36.7)0.1125
 • Arthtralgia (%)71 (19.1)76 (23.4)0.1198
Localizations of disease
 • Isolated pulmonary284 (76.7)143 (44.1%)<0.0001
 • Lung + extrapulmonary55 (14.8%)111 (34.2%)<0.0001
 • Extrapulmonary only31 (8.3%)70 (21.6%)<0.0001
Clinical phenotypes
 • Abdominal (%)14 (3.7)16 (4.9)<0.0001
 • OCCC (%)12 (3.2)20 (6.1)<0.0001
 • Muscoloskeletal-cutaneous (%)35 (9.4)78 (24)<0.0001
 • Isolated pulmonary (%)284 (76.7)143 (44.1)<0.0001
 • Extrapulmonary (%)25 (6.7)67 (20.6)<0.0001
Lab parameters
 • 24 h urine calcium mg/dl177.1 ± 136.8222.6 ± 139.90.0289
COS classification247309 
 • 1 (%)49 (19.8)0<0.0001
 • 2 (%)50 (20.2)0<0.0001
 • 3 (%)33 (13.3)0<0.0001
 • 4 (%)29 (11.7)0<0.0001
 • 5 (%)31 (12.5)0<0.0001
 • 6 (%)55 (22.2)10 (3.2)<0.0001
 • 7 (%)0112 (36.2)<0.0001
 • 8 (%)0151 (48.8)<0.0001
 • 9 (%)036 (11.6)<0.0001
  1. PFT pulmonary function test, COS clinical outcome status and biomarker assessment in steroid-free and treated sarcoidosis patients, GERD gastro-esophageal reflux disease